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Background: Effective tight glycemic control (TGC) can improve outcomes in critical care patients, but it is difficult to
achieve consistently. Insulin sensitivity defines the metabolic balance between insulin concentration and insulin-mediated
glucose disposal. Hence, variability of insulin sensitivity can cause variable glycemia. This study quantifies and compares
the daily evolution of insulin sensitivity level and variability for critical care patients receiving TGC.
Methods: This is a retrospective analysis of data from the SPRINT TGC study involving patients admitted to a mixed
medical-surgical ICU between August 2005 and May 2007. Only patients who commenced TGC within 12 hours of ICU
admission and spent at least 24 hours on the SPRINT protocol were included (N=164). Model-based insulin sensitivity (SI)
was identified each hour. Absolute level and hour-to-hour percent changes in SI were assessed on cohort and per-patient
bases. Levels and variability of SI were compared over time on 24-hour and 6-hour timescales for the first 4 days of ICU
stay.
Results: Cohort and per-patient median SI levels increased by 34% and 33% (p< 0.001) between days 1 and 2 of ICU
stay. Concomitantly, cohort and per-patient SI variability decreased by 32% and 36% (p< 0.001). For 72% of the cohort,
median SI on day 2 was higher than on day 1. The day 1–2 results are the only clear, statistically significant trends across
both analyses. Analysis of the first 24 hours using 6-hour blocks of SI data showed that most of the improvement in
insulin sensitivity level and variability seen between days 1 and 2 occurred during the first 12–18 hours of day 1.
Conclusions: Critically ill patients have significantly lower and more variable insulin sensitivity on day 1 than later in
their ICU stay and particularly during the first 12 hours. This rapid improvement is likely due to the decline of
counter-regulatory hormones as the acute phase of critical illness progresses. Clinically, these results suggest that while
using TGC protocols with patients during their first few days of ICU stay, extra care should be afforded. Increased
measurement frequency, higher target glycemic bands, conservative insulin dosing, and modulation of carbohydrate
nutrition should be considered to minimize safely the outcome glycemic variability and reduce the risk of
hypoglycemia.
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t1:1Table 1 Summary details of the study subjects
t1:2N 164
t1:3Age (yr) 65 [56–74]
t1:4Gender (M/F) 102/62
t1:5APACHE II score 19 [16–25]
t1:6APACHE II ROD (%) 32 [17–52]
t1:7Operative/nonoperative 66/98
t1:8Hospital mortality 25%
t1:9ICU mortality 18%
t1:10ICU length of stay (hr) 142 [70–308]
t1:11Diabetic history: type I/type II 10/22
t1:12Data are presented as median [interquartile range] where appropriate.
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Safe, effective tight glycemic control (TGC) of critically ill
patients can improve outcomes [1-4], but it is difficult to
achieve consistently [5-7]. Glycemic level and variability in
TGC are a function of variability in insulin sensitivity,
potentially resulting from the level and evolution of the
stress response [8], and are independently associated with
mortality [9-12].
Insulin sensitivity defines the metabolic balance be-
tween insulin concentration and glucose disposal.
Insulin-mediated glucose disposal is a dominant pathway
to reduce and control glycemia in critically ill patients.
For a fixed insulin concentration, a given percentage
change of insulin sensitivity results in a proportional
change to glucose disposal and thus glycemic level, all
else equal.
Understanding the variability of insulin sensitivity, over
hours and days, is important for safely and effectively
managing glycemic levels with exogenous insulin. Several
patient- and treatment-related factors influence insulin
sensitivity. Some of the influential and predictable factors
(drug therapies and existing patient conditions) are taken
into account when developing therapeutic algorithms for
insulin treatment.
The objective of this study was to examine the evolution
of insulin sensitivity level and variability over the first
4 days of intensive care unit (ICU) stay using data from
the SPRINT TGC study [1]. Analyses were performed on
two separate timescales, using 24-hour and 6-hour blocks
of data. The impact of this insulin sensitivity evolution on
glycemia in the context of TGC protocols is considered.
Methods
Patients
This study is a retrospective analysis of patient data
(N= 164 patients, 12,067 hours) from the SPRINT clin-
ical practise change in the Christchurch Hospital ICU
[1]. All patients admitted between August 2005 and May
2007 were included where the SPRINT TGC protocol
was commenced within 12 hours of ICU admission and
continued for at least 24 hours. All patients were treated
per protocol, with no specific exclusions. Table 1 pre-
sents a summary of cohort details.
The Christchurch Hospital ICU is a 15-bed, closed,
mixed medical-surgical unit led by intensive care specialists
in a tertiary affiliated teaching hospital. Glycemic control
data were collected from handwritten daily ICU charts and
entered into a spreadsheet database. The Upper South
Regional Ethics Committee, New Zealand, granted approval
for the audit, analysis, and publication of this data.
The SPRINT protocol
The SPRINT protocol (SPecialised Relative Insulin
Nutrition Tables) is a simple, lookup-table system derivedfrom a model-based controller that modulates both insu-
lin and nutritional inputs. The protocol titrates insulin
doses and nutrition rates to estimated patient-specific
insulin sensitivity for tight glycemic control in the range
4.0–6.1 mmol/L BG range [1,13,14]. SPRINT has been the
standard of care in the Christchurch ICU since August
2005. The requirement for the patients in this study to be
on the SPRINT protocol ensured that they had regular
and accurate records of blood glucose levels, insulin admi-
nistered, and nutrition given.
The entry criterion for the SPRINT protocol was two
BG measurements >8 mmol/L during normal patient
monitoring, or at the discretion of the clinician. Once
on the protocol, BG was measured 1- to 2-hourly, with a
median measurement interval for this cohort of 1.5
hours. BG measurements were taken by nursing staff
using the Arkray Super-Glucocard II glucometer (Arkray
Inc., Japan). Blood samples tested were typically arterial,
although when an arterial line was not present, capillary
blood was used. Additional File 1 contains a more
detailed description of SPRINT and specific, unique dif-
ferences to other protocols.
Model-based insulin sensitivity
Model-based methods provide a means of determining
physiological parameters that either cannot be measured
directly or are impractical to measure with the required
frequency. In this study, model-based insulin sensitivity
(SI) was identified using an integral method [15] with a
validated glucose-insulin system model developed for
critical care patients [16,17]. The glucose-insulin system
model is illustrated schematically in Figure 1 and pre-
sented in greater detail in Additional File 2.
The SI parameter represents “whole-body” insulin sensi-
tivity. The parameter defines the glycemic response to
exogenous insulin and nutrition, capturing the relative net
effect of altered endogenous glucose production, periph-
eral and hepatic insulin mediated glucose uptake, and
endogenous insulin secretion. However, this time-varying
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Figure 1 Schematic illustration of the glucose-insulin system model used in this analysis.
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http://www.annalsofintensivecare.com/content/2/1/17insulin sensitivity parameter has been shown to correlate
very well (r> 0.9) with the “gold standard” euglycemic
clamp [17] and has been used to guide model-based TGC
in several studies [18-20].
A value of SI was identified every hour [15] for each pa-
tient using clinical data and the model implemented in
MATLAB (2011a, Mathworks, Natick, MA). When the
BG measurement interval was greater than 1 hour, linearly
interpolated values were used for identification. Variability
of insulin sensitivity was calculated as the hour-to-hour
percentage change in SI (Δ%SI), defined below:
Δ%SIk ¼ 100 SIkþ1  SIkð ÞSIk
Use of percentage change in SI, rather than absolute
change, normalizes the metric so that patients with very
different absolute levels of SI can be compared fairly.
Equally, for a fixed insulin concentration, a given percent-
age change in insulin sensitivity results in a proportional
change to glucose disposal and thus glycemic level, all else
equal.
Analyses
SI level and variability are analyzed on overall cohort
and per-patient bases using two separate timescales. Theevolution of SI over the first 4 days of ICU stay is ana-
lyzed in 24-hour blocks. Bagshaw [12] reported an asso-
ciation between hypoglycemia and variability during the
first 24 hours of ICU stay and mortality. We therefore
also analyzed the acute evolution of SI over the first day
using 6-hour blocks.
Cohort analysis looks at the hourly values of SI and vari-
ability for the entire cohort grouped together and shows
trends in the overall group behavior. To quantify per-
patient variability, the interquartile range (IQR: 25th–75th
percentile) of Δ%SI is examined for each patient within
each timescale. This metric captures the width of the vari-
ability distribution for each patient. Per-patient SI level is
defined by the median value within each timescale.
The analyses are linked to time on the SPRINT proto-
col, rather than time in the ICU, to ensure sufficient insu-
lin and nutrition data to accurately identify SI hourly [15].
Hence, day 1 comprises the first 24 hours of SPRINT.
However, because patients were included only if they
commenced SPRINT within 12 hours of ICU admission, a
minimum of half of the day 1 results for each patient
occur during their first 24 hours in the ICU. The median
delay between admission and commencement of SPRINT
for this cohort was 1.9 hours and 81% of the cohort was
on SPRINT within 6 hours. When a patient was taken off
the SPRINT protocol, their SI profile for the last day was
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t2:1Table 2 Increasing cohort and per-patient median insulin
t2:2sensitivity over time (24-hr blocks)
t2:3Level
t2:4analysis
Cohort analysis Per-patient analysis
t2:5% Increase
t2:6at median
p value % Increase
at median
p value
t2:7Days 1-2 34 <0.0001 33 0.0004
t2:8Days 2-3 16 <0.0001 21 0.2559
t2:9Days 3-4 6 0.0013 4 0.6306
t2:10P values calculated using Wilcoxon rank-sum test.
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http://www.annalsofintensivecare.com/content/2/1/17included in the analysis only if it contained 6 hours or
more of data.
SI levels and variability are non-Gaussian and thus
compared using cumulative distribution functions
(CDFs) and nonparametric statistics. Distributed data
are generally compared using the Wilcoxon rank-sum
test (Mann–Whitney U test), except for SI variability
results. SI variability is compared using the Kolmogorov-
Smirnov test, because it has more power to detect differ-
ences in the shape of distributions than the rank-sum
test when median values are similar. P< 0.05 are consid-
ered statistically significant.
Results
Twenty-four hour analyses
Insulin sensitivity level
Figure 2 presents the cumulative distribution functions
(CDFs) of hourly SI for each day by cohort (left panel) and
median daily SI per-patient (right panel). Table 2 presents
the increase in median insulin sensitivity and associated
p values between successive days. Both per-patient and co-
hort analyses suggest that insulin sensitivity levels start
low, but increase over time in the ICU. There is a particu-
larly significant increase between days 1 and 2 (p< 0.001).
On subsequent days the increase continues but to a lesser
degree. Per-patient comparisons between days 2, 3, and 4
are not statistically significant.
The results of Figure 2 and Table 2 are further reflected
in Table 3, which shows that daily median insulin sensitiv-
ity increases for a large proportion of the cohort between
days 1 and 2 with lesser proportions on subsequent days.
Table 3 is a matrix where the value in a cell represents the0 0.5 1 1.5
x 10-3
0
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0.7
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0.9
1
Cohort level analysis 
SI [L/mU.min] 
F(
x) 
0-24hrs (3936 hours)
24-48hrs (3376 hours)
48-72hrs (2568 hours)
72-96hrs (2187 hours)
Figure 2 Insulin sensitivity level distributions by cohort (left) and perproportion of patients for whom daily median insulin sen-
sitivity is greater on the day of the associated column than
the day of the associated row. For example, 72% of
patients show an increase in median SI between days 1
and 2, and 54% when comparing days 2 and 3.
Insulin sensitivity variability
SI variability decreases over time in the ICU, parallel to
increases in absolute SI level. Figure 3 and Table 4
present the CDFs and tabulated results for cohort and
per-patient analyses of the hour-to-hour percentage
changes in SI (Δ%SI). The cohort aggregate distributions
of Δ%SI by day are shown in the left panel of Figure 3.
The right panel presents the CDFs for the per-patient
IQRs by day.
As with insulin sensitivity level, the largest increase in
SI variability is between days 1 and 2. The decrease
between days 2, 3, and 4 is statistically significant for
both cohort and per-patient analyses, but the change is
much less than over the first day and may not be clinic-
ally significant.0 0.5 1 1.5
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Per-patient level analysis 
SI [L/mU.min] 
F(
x) 
0-24hrs (164 patients)
24-48hrs (155 patients)
48-72hrs (112 patients)
72-96hrs (95 patients)
-patient median (right) using 24-hr blocks of data.
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t4:1Table 4 Reductions in the interquartile range (IQR) and
t4:2median per-patient range of hour-to-hour percentage
t4:3insulin sensitivity change over time
t4:4Variability
t4:5analysis
Cohort analysis Per-patient analysis
t4:6% Reduction
t4:7of IQR
p-value % Decrease
at median
p value
t4:8Days 1-2 32 <0.0001 36 <0.0001
t4:9Days 2-3 20 0.0028 18 0.0091
t4:10Days 3-4 14 0.0269 17 0.0369
t4:11P values calculated using Kolmogorov-Smirnov test for cohort comparisons
t4:12and Wilcoxon rank-sum test for per-patient comparisons.
t3:1 Table 3 Proportion of patients for whom median insulin
t3:2 sensitivity increases between the days indicated in the
t3:3 rows and columns
t3:4 Day 2 Day 3 Day 4
t3:5 Day 1 0.72 0.74 0.71
t3:6 Day 2 0.54 0.64
t3:7 Day 3 0.53
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Insulin sensitivity level
Figure 4 presents the distributions of cohort and per-
patient insulin sensitivity over the first 24 hours in 6-
hour blocks. Also shown for comparison is the day 2 dis-
tribution from Figure 1 (labeled 24–28 hours). It is evi-
dent that the insulin sensitivity level increases over the
first day up to the level of the second day. Hence, the
differences between day 1 and 2 seen in Figure 2 are a
function of the low, but increasing, insulin sensitivity
during the first 12–18 hours.
Table 5 lists the differences in median insulin sensitiv-
ity levels from the distributions shown in Figure 4. The
increases in SI during the first 18 hours are large and
statistically significant. Subsequent increases are unlikely
to be clinically significant at less than 10%. Of particular
interest is the comparison between 18–24 hours and day
2, which indicates that by 18 hours, the rapid increase in
SI is largely complete.
Table 6 shows that during the first 18 hours, a large
proportion of the patients have an increase of insulin
sensitivity using the 6-hour timescale. After 18 hours,-100 -80 -60 -40 -20 0 20 40 60 80 1000
0.1
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0.3
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0.6
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0.9
1
Cohort variability analysis 
Percentage change (%) 
F(x
) 
0-24hrs (3772 hours)
24-48hrs (3221 hours)
48-72hrs (2456 hours)
72-96hrs (2092 hours)
Figure 3 Insulin sensitivity variability distributions by cohort (hour-to
using 24 hr blocks of data.the proportion of patients with increasing SI is similar to
that seen between days 2, 3, and 4 (Table 3) at slightly
more than 50%.
Insulin sensitivity variability
As with absolute SI level, the majority of the decrease in
SI variability occurred during the first 18 hours. Figure 5
shows the CDFs of the cohort and per-patient variability
metrics. Table 7 shows that only the differences between
0–6 hours and 6–12 hours are statistically significant at
the 5% level. The 6–12 vs. 12–18-hour comparison is
close to statistical significance, with p< 0.07 for both
cohort and per-patient analyses.
Discussion
Insulin sensitivity variability
Both cohort and per-patient results suggest that critically
ill patients have significantly lower and more variable
insulin sensitivity on day 1 than later in their ICU stay.0 50 100 150 200 250 300 350 4000
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Figure 4 Insulin sensitivity level distributions by cohort (left) and per-patient median (right) using 6-hr blocks of data.
t5:1
t5:2
t5:3
t5:4
t5:5
t5:6
t5:7
t5:8
t5:9
t5:10
t5:11
t5:12
t5:13
t5:14
Pretty et al. Annals of Intensive Care 2012, 2:17 Page 6 of 10
http://www.annalsofintensivecare.com/content/2/1/17Further analysis shows that this day 1 result is primarily
influenced by the first 12–18 hours of ICU stay. Over this
time, rapid improvements in insulin sensitivity level and
variability occur so that there is no statistically significant
difference between 18–24 hours and day 2. From day 2
onwards, changes in SI level and variability are not as large
and of limited clinical and statistical significance.
Within the analyses, there are some differences in
significance between cohort and per-patient results for
comparisons after day 2. The overall findings noted in the
preceding paragraph are the only clear, consistent trends
across both analyses.
The counter-regulatory hormones: cortisol, glucagon,
the catecholamines, as well as growth hormone are signifi-
cantly elevated almost immediately after critical-insult,
but decline rapidly over the first 12–48 hours [21-24].
These hormones are known to cause increased hepatic292
293
294
295
296
Table 5 Increasing cohort and per-patient median insulin
sensitivity over time (6-hr blocks)
Level analysis Cohort analysis Per-patient analysis
% Increase
at median
p value % Increase
at median
p value
Block 1–2
(0–6 vs. 6–12 hr)
42 <0.0001 40 0.0007
Block 2–3
(6–12 vs. 12–18 hr)
28 <0.0001 26 0.0123
Block 3–4
(12–18 vs. 18–24 hr)
1 0.0335 3 0.4829
Block 4–5
(18–24 vs. 24–48 hr)
9 0.0452 7 0.3776
P values calculated using Wilcoxon rank-sum test.glucose production, inhibition of insulin release, and
peripheral insulin resistance [22], all of which cause a
decrease in the model-based SI metric used in this study.
Hence, the low but rapidly increasing insulin sensitivity
seen during the first 12–18 hours of ICU stay is likely due
to the acute counter-regulatory response to critical illness.
Time in this study was referenced from the com-
mencement of SPRINT, rather than ICU admission.
However, the difference between admission time and
commencing SPRINT was generally very short, with a
median delay for this cohort of 1.9 hours. Within 6
hours of admission, 81% of the cohort had commenced
SPRINT. Hence, these results are applicable to the first
few hours and days of ICU stay.
The insulin sensitivity parameter
The model-based parameter used in this study repre-
sents a whole-body insulin sensitivity capturing overall
metabolic response to exogenous insulin. SI captures the
relative net effect of altered hepatic glucose production,
peripheral and hepatic insulin-mediated glucose uptake,
and endogenous insulin secretion. All of these effectst6:1Table 6 Proportion of patients for whom median insulin
t6:2sensitivity increases between the blocks indicated in the
t6:3rows and columns
t6:46–12 hr 12–18 hr 18–24 hr 24–48 hr
t6:50–6 hr 0.74 0.78 0.77 0.79
t6:66–12 hr 0.76 0.7 0.72
t6:712–18 hr 0.55 0.64
t6:818–24 hr 0.58
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Figure 5 Insulin sensitivity variability distributions by cohort (hour-to-hour percentage change) and per-patient interquartile-range
using 6-hr blocks of data.
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http://www.annalsofintensivecare.com/content/2/1/17are altered significantly in critical illness due to the
stress response [25-27]. Hence, the metabolic balance
that this parameter represents is an important consider-
ation in TGC, because it determines a body’s glycemic
response to exogenous insulin and nutrition.
As an identified parameter, SI contains unmodeled
physiological effects and measurement device noise. How-
ever, Lotz et al. [17] indicated that this form of insulin sen-
sitivity correlated very well (r> 0.9) with the “gold
standard” euglycemic clamp and its change in a lifestyle
intervention study on 73 normoglycemic healthy and
obese subjects (146 clamp procedures before/after inter-
vention). In the critical care setting, a similar version of
the model and SI parameter has been cross-validated324
325
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Table 7 Reductions of the interquartile range (IQR) and
median per-patient range of hour-to-hour percentage
insulin sensitivity change over time
Variability
analysis
Cohort analysis Per-patient analysis
% Reduction
of IQR
p value % Decrease
at median
p value
Block 1–2
(0–6 vs. 6–12 hr)
40 0.0017 36 <0.0001
Block 2–3
(6–12 vs. 12–18 hr)
24 0.0628 28 0.0673
Block 3–4
(12–18 vs. 18–24 hr)
0 0.0931 9 0.1032
Block 4–5
(18–24 vs. 24–48 hr)
18 0.1682 14 0.1075
P values calculated using Kolmogorov-Smirnov test for cohort comparisons
and Wilcoxon rank-sum test for per-patient comparisons.against independent, matched patient data from a single
center of the Glucontrol randomized, clinical trial [28].
The analytic inaccuracy of bedside glucometers or any
other sensor used to gather BG measurements influence
individual values of SI. However, this study examines
distributions of SI consisting of thousands of values
identified from a wide range of BG values, thus both the
random and bias components of error cancel out within
each distribution. This effect was confirmed by Monte
Carlo analysis (results not shown) using an error model
for the glucometer derived from data supplied by the
manufacturer [29].
Implications for tight glycemic control
With low and variable insulin sensitivity, glycemic levels
may appear unresponsive and/or difficult to control effect-
ively with exogenous insulin. This situation may provoke
larger insulin doses from many protocols that have no
explicit upper limits on insulin dose [6,30-32]. High levels
of circulating insulin coupled with the observed variability
in insulin sensitivity result in increased glycemic variability
and an increased risk of hypoglycemia during the first 24
hours of ICU stay.
Not only does glycemic variability pose a risk through
hypoglycemia, it also is detrimental in its own right. Several
studies [9-11,33] have shown that glycemic variability is
independently associated with mortality in critically ill
patients. More specifically, Bagshaw [12] showed that
hypoglycemia and variability within the first 24 hours of
ICU stay are each associated with increased mortality. In
vitro, high glycemic variability was shown to increase
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http://www.annalsofintensivecare.com/content/2/1/17oxidative stress [34] and apoptosis [35], thereby suggesting
a rationale to explain the clinical association with poor
outcome.
Evidence from other studies [10,12] indicates an associ-
ation between hypoglycemia, glycemic variability, and mor-
tality. However, the question remains: Is low and variable
glycemia the cause of increased morbidity and mortality?
Or is it just a symptom in very ill patients? Until this ques-
tion can be answered conclusively, it is perhaps best to for-
mulate TGC protocols not to exacerbate the situation,
which requires the ability to differentiate more and less
metabolically variable patients.
Another significant finding in this study is the range of
variability seen across patients, as well as over time
(Figures 3 and 5). Less variable patients, if identified, may
be treated more aggressively with insulin without com-
promising glycemic variability. Hence, model-based meth-
ods have been mooted as a means of better managing this
inter- and intra-patient variability [30,36].
Limitations
Only patients on the SPRINT TGC protocol were consid-
ered for this analysis as they had sufficient data density to
identify SI hourly. Patients were put on the SPRINT
protocol because they were hyperglycemic and thus were
likely to be biased towards lower insulin sensitivity com-
pared with other ICU patients. However, in the context of
investigating the implications of SI variability on TGC,
this cohort is appropriate.
Another limitation is the use of a model-based insulin
sensitivity parameter, as it is not measured directly and
may be influenced by modelling errors or un-modelled
effects. As an identified parameter, SI contains unmo-
deled physiological effects and measurement device
noise. However, as noted previously, this form of SI has
been shown to correlate very well with the “gold stand-
ard” euglycemic clamp [17,37] and has been shown to
be an independent marker of metabolic condition [28].
Finally, this method of analysis is robust to BG sensor
error.
A further limitation is the relatively small cohort size
available for analysis. The demands of manually tran-
scribing written clinical data into electronic form and
the specific inclusion criteria have restricted the number
of patients for whom complete glycemic control data are
currently available for analysis. The size of this cohort
has precluded subgroup analyses, such as diabetic and
cardiovascular surgery patients, because these subgroups
only contain 20–40 patients. With relatively few
patients, the subgroup analyses fail to demonstrate stat-
istical significance, despite effect sizes and trends very
similar to that seen in this overall analysis. Thus, these
comparisons will be completed in the future, when more
patient data become available.The findings of this study should be equally valid in
other ICUs where attention to TGC and blood glucose
measurement frequency may be a lower priority. Al-
though the data density might not be present to allow
such units to explicitly identify SI hourly, these results
indicate that patients will still have lower and more vari-
able insulin sensitivity on day 1 than later in their ICU
stay. Thus, suggestions of higher glycemic targets, con-
servative insulin dosing, and modulation of carbohydrate
nutrition are especially pertinent.
Without the ability to identify patient-specific metabolic
states, a protocol should be less aggressive over the first
few days, and particularly the first 24 hours, to minimize
variability. It may be important for protocols to consider
higher glycemic targets on the first days of ICU stay (com-
pared with later days) to ensure safety. Perhaps a glycemic
target similar to the current guidelines of 7.8-11 mmol/L
[38-40] is most appropriate for the first 24 hours with the
target range, reducing over days 2 and 3 to more normo-
glycemic levels as SI level and variability improve.
Greater blood glucose measurement frequency and
conservative insulin dosing can mitigate the impact of SI
variability on risk [41] and also should be considered for
the first few days of stay. Modulation of carbohydrate
nutrition, within limits [42], can reduce the need for ex-
ogenous insulin to better manage glycemia [43].
Conclusions
The results of this study indicate that critically ill patients
have significantly lower and more variable insulin sensitivity
on day 1 than later in their ICU stay, particularly during the
first 12–18 hours. This effect is likely due to the acute
counter-regulatory response to critical illness. Greater vari-
ability with lower SI early in a patient’s stay greatly increases
the insulin required, potential glucose flux due to variation
in SI, and thus the risk of greater glycemic variability and
hypoglycemia. Both glycemic variability and hypoglycemia
have been associated with poor outcomes in the ICU.
Clinically, these results suggest that TGC patients re-
quire greater care over the first few days of ICU stay to
minimize safely the outcome glycemic variability. It may
be important for protocols to consider higher glycemic
targets on the first days of ICU stay to ensure safety.
Equally, greater measurement frequency, conservative
insulin dosing, and modulation of carbohydrate nutrition
can mitigate the impact of variability on risk and should
be considered for the first few days of stay.
Additional files
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